rAAVrh74.MHCK7.micro-dystrophin静脉递送治疗杜氏肌营养不良儿童的非随机对照试验
该开放标签1/2a期非随机对照试验在Nationwide儿童医院纳入4例符合条件的可行走男性DMD患儿,单次静脉输注2.0×10^14 vg/kg rAAVrh74.MHCK7.micro-dystrophin并配合泼尼松龙。1年内全部不良事件为轻至中度、无严重不良事件,12周时腓肠肌活检显示微抗肌萎缩蛋白广泛表达,NSAA评分改善且肌酸激酶降低并维持1年。
要点
- 单次静脉输注2.0×10^14 vg/kg耐受性良好,53例次不良事件均为轻至中度,无严重不良事件。
- 12周时平均81.2%肌纤维表达微抗肌萎缩蛋白,平均强度96%,Western blot校正后平均表达95.8%。
- NSAA评分改善与肌酸激酶降低维持1年,提示功能获益可能优于标准治疗。
核心结论
- rAAVrh74.MHCK7.micro-dystrophin静脉递送耐受性良好、不良事件轻微,可实现微抗肌萎缩蛋白的安全递送、稳健表达与正确亚细胞定位。
- 治疗伴随肌酸激酶水平与NSAA评分的改善,提示其功能获益可能大于标准治疗下观察到的水平。
研究设计与样本
- 开放标签、1/2a期非随机对照试验,在俄亥俄州哥伦布市Nationwide儿童医院开展。
- 纳入前4例符合条件者:可行走男性DMD患儿,无预存AAVrh74抗体,皮质类固醇剂量稳定≥12周。
主要发现
- 共纳入4例患者,入组时平均(SD)年龄4.8(1.0)岁。
- 全部不良事件(n=53)为轻度33例次(62%)或中度20例次(38%),无严重不良事件;18例次被认为与治疗相关,最常见为呕吐(18例次中9例次,50%)。
- 3例患者出现短暂性γ-谷氨酰转移酶升高,经皮质类固醇治疗后缓解。
- 12周时腓肠肌活检免疫组化显示全部患者转基因稳健表达,平均81.2%肌纤维表达微抗肌萎缩蛋白,肌膜处平均强度96%;Western blot示未校正脂肪或纤维化时平均表达74.3%,校正后95.8%。
- 全部患者确认载体转导,NSAA评分功能改善且肌酸激酶水平(治疗后vs基线)降低,并维持1年。
关键数值与推荐
- 干预为单次剂量2.0×10^14 vg/kg rAAVrh74.MHCK7.micro-dystrophin,经外周肢体静脉输注。
- 基因递送前1天开始每日泼尼松龙1 mg/kg,输注后30天内逐渐减量。
临床怎么用
- 研究提示单次静脉输注该微抗肌萎缩蛋白基因治疗在DMD患儿中安全性可接受,并可获得稳健的肌肉转基因表达。
- 治疗前后需监测不良事件(如呕吐)及γ-谷氨酰转移酶,必要时用皮质类固醇处理。
- NSAA与肌酸激酶可作为评估功能与生物化学获益的随访指标。
局限性
- 样本量仅4例,为非随机开放标签设计,缺乏对照组的同期比较。
- 随访报告主要覆盖1年安全性及部分探索性功能结局,长期疗效与安全性尚待更长时间随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Micro-dystrophin gene transfer shows promise for treating patients with Duchenne muscular dystrophy (DMD) using recombinant adeno-associated virus serotype rh74 (rAAVrh74) and codon-optimized human micro-dystrophin driven by a skeletal and cardiac muscle-specific promoter with enhanced cardiac expression (MHCK7). OBJECTIVE: To identify the 1-year safety and tolerability of intravenous rAAVrh74.MHCK7.micro-dystrophin in patients with DMD. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 1/2a nonrandomized controlled trial was conducted at the Nationwide Children's Hospital in Columbus, Ohio. It began on November 2, 2017, with a planned duration of follow-up of 3 years, ending in March 2021. The first 4 patients who met eligibility criteria were enrolled, consisting of ambulatory male children with DMD without preexisting AAVrh74 antibodies and a stable corticosteroid dose (≥12 weeks). INTERVENTIONS: A single dose of 2.0 × 1014 vg/kg rAAVrh74.MHCK7.micro-dystrophin was infused through a peripheral limb vein. Daily prednisolone, 1 mg/kg, started 1 day before gene delivery (30-day taper after infusion). MAIN OUTCOMES AND MEASURES: Safety was the primary outcome. Secondary outcomes included micro-dystrophin expression by Western blot and immunohistochemistry. Functional outcomes measured by North Star Ambulatory Assessment (NSAA) and serum creatine kinase were exploratory outcomes. RESULTS: Four patients were included (mean [SD] age at enrollment, 4.8 [1.0] years). All adverse events (n = 53) were considered mild (33 [62%]) or moderate (20 [38%]), and no serious adverse events occurred. Eighteen adverse events were considered treatment related, the most common of which was vomiting (9 of 18 events [50%]). Three patients had transiently elevated γ-glutamyltransferase, which resolved with corticosteroids. At 12 weeks, immunohistochemistry of gastrocnemius muscle biopsy specimens revealed robust transgene expression in all patients, with a mean of 81.2% of muscle fibers expressing micro-dystrophin with a mean intensity of 96% at the sarcolemma. Western blot showed a mean expression of 74.3% without fat or fibrosis adjustment and 95.8% with adjustment. All patients had confirmed vector transduction and showed functional improvement of NSAA scores and reduced creatine kinase levels (posttreatment vs baseline) that were maintained for 1 year. CONCLUSIONS AND RELEVANCE: This trial showed rAAVrh74.MHCK7.micro-dystrophin to be well tolerated and have minimal adverse events; the safe delivery of micro-dystrophin transgene; the robust expression and correct localization of micro-dystrophin protein; and improvements in creatine kinase levels and NSAA scores. These findings suggest that rAAVrh74.MHCK7.micro-dystrophin can provide functional improvement that is greater than that observed under standard of care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03375164.
引用
- Mendell JR, Sahenk Z, Lehman K, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020. PMID: 32539076. doi:10.1001/jamaneurol.2020.1484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。